96 related articles for article (PubMed ID: 31688381)
1. Meige Syndrome Related to Vortioxetine in 2 Sisters: Case Reports.
Kocamer Şahin Ş; Elboga G; Altindag A
J Clin Psychopharmacol; 2019; 39(6):679-681. PubMed ID: 31688381
[No Abstract] [Full Text] [Related]
2. Vortioxetine for Depression in Adults.
Long JD
Issues Ment Health Nurs; 2019 Sep; 40(9):819-820. PubMed ID: 31225773
[No Abstract] [Full Text] [Related]
3. Restless Legs Syndrome Related to Vortioxetine: A Case Report.
Romigi A; Vitrani G; Caccamo M; Centonze D
J Clin Psychopharmacol; 2019; 39(5):514-516. PubMed ID: 31433340
[No Abstract] [Full Text] [Related]
4. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder.
Gonda X; Sharma SR; Tarazi FI
Expert Opin Drug Discov; 2019 Jan; 14(1):81-89. PubMed ID: 30457395
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study.
De Carlo V; Vismara M; Grancini B; Benatti B; Bosi MF; Colombo A; Viganò CA; Dell'Osso B
Hum Psychopharmacol; 2020 Sep; 35(5):e2750. PubMed ID: 32662933
[TBL] [Abstract][Full Text] [Related]
6. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders.
Findling RL; Robb AS; DelBello MP; Huss M; McNamara NK; Sarkis EH; Scheffer RE; Poulsen LH; Chen G; Lemming OM; Auby P
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):47-54. PubMed ID: 29035574
[TBL] [Abstract][Full Text] [Related]
7. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine for the treatment of major depression.
Dhir A
Drugs Today (Barc); 2013 Dec; 49(12):781-90. PubMed ID: 24524096
[TBL] [Abstract][Full Text] [Related]
9. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Feb; 69(2):151-5. PubMed ID: 25627335
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.
Dubovsky SL
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):759-66. PubMed ID: 24684240
[TBL] [Abstract][Full Text] [Related]
11. Meige syndrome with apraxia of lid opening after the discontinuation of sulpiride treatment.
Tsuji S; Kikkawa S; Horiguchi J; Yamashita H; Kagaya A; Morinobu S; Yamawaki S
Pharmacopsychiatry; 2002 Jul; 35(4):155-6. PubMed ID: 12163987
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
15. Vortioxetine-Induced Amenorrhea: A Case Report.
Işik M; Kurhan F; Ülkevan T; Özdemir PG
Clin Neuropharmacol; 2022 Jan-Feb 01; 45(1):7-8. PubMed ID: 35029863
[TBL] [Abstract][Full Text] [Related]
16. An overview of vortioxetine.
Schatzberg AF; Blier P; Culpepper L; Jain R; Papakostas GI; Thase ME
J Clin Psychiatry; 2014 Dec; 75(12):1411-8. PubMed ID: 25551236
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
Meeker AS; Herink MC; Haxby DG; Hartung DM
Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
Christensen MC; Florea I; Lindsten A; Baldwin DS
J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
[TBL] [Abstract][Full Text] [Related]
19. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Christensen MC; Munro V
Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
